%0 Journal Article
%A Ahadova, Aysel
%A Witt, Johannes
%A Haupt, Saskia
%A Gallon, Richard
%A Hüneburg, Robert
%A Nattermann, Jacob
%A Ten Broeke, Sanne
%A Bohaumilitzky, Lena
%A Hernandez-Sanchez, Alejandro
%A Santibanez-Koref, Mauro
%A Jackson, Michael S
%A Ahtiainen, Maarit
%A Pylvänäinen, Kirsi
%A Andini, Katarina
%A Grolmusz, Vince Kornel
%A Möslein, Gabriela
%A Dominguez-Valentin, Mev
%A Møller, Pål
%A Fürst, Daniel
%A Sijmons, Rolf
%A Borthwick, Gillian M
%A Burn, John
%A Mecklin, Jukka-Pekka
%A Heuveline, Vincent
%A von Knebel Doeberitz, Magnus
%A Seppälä, Toni
%A Kloor, Matthias
%T Is HLA type a possible cancer risk modifier in Lynch syndrome?
%J International journal of cancer
%V 152
%N 10
%@ 0020-7136
%C Bognor Regis
%I Wiley-Liss
%M DKFZ-2022-02503
%P 2024-2031
%D 2023
%Z #EA:F210#LA:F210# / 2023 May 15;152(10):2024-2031
%X Lynch syndrome (LS) is the most common inherited cancer syndrome. It is inherited via a monoallelic germline variant in one of the DNA mismatch repair (MMR) genes. LS carriers have a broad 30
%K HLA genotype (Other)
%K Lynch syndrome (Other)
%K cancer immunoediting (Other)
%K immune surveillance (Other)
%K personalized cancer risk (Other)
%F PUB:(DE-HGF)16
%9 Journal Article
%$ pmid:36214792
%R 10.1002/ijc.34312
%U https://inrepo02.dkfz.de/record/182209